Do analysts recommend AXSM or GMTX?

Axsome Therapeutics presently has a consensus price target of $261.48, suggesting a potential upside of 8.50%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 2 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 2.91 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ABVX or GMTX?

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 24.50%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Abivax is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.80 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ABVX or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is ABVX or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Gemini Therapeutics N/A -38.78% -35.88%

Do analysts rate GMTX or SMMT?

Summit Therapeutics has a consensus target price of $26.15, indicating a potential upside of 91.47%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Summit Therapeutics 2 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.44

Which has preferable earnings and valuation, GMTX or SMMT?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is GMTX or SMMT more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Summit Therapeutics N/A -183.84% -154.65%

Do analysts prefer GMTX or ARWR?

Arrowhead Pharmaceuticals has a consensus price target of $93.83, suggesting a potential upside of 9.62%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71

Gemini Therapeutics (GMTX) Competitors

$75.86 +1.54 (+2.07%)

As of 07/23/2026

Compare

GMTX vs. ELAN, AXSM, ABVX, SMMT, and ARWR

Should you buy Gemini Therapeutics stock or one of its competitors? MarketBeat compares Gemini Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gemini Therapeutics include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Abivax (ABVX), Summit Therapeutics (SMMT), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Gemini Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Gemini Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.54	-$232M	-$0.50	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Elanco Animal Health presently has a consensus price target of $28.73, indicating a potential upside of 15.37%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe Elanco Animal Health is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Elanco Animal Health had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 0 mentions for Gemini Therapeutics. Elanco Animal Health's average media sentiment score of 1.27 beat Gemini Therapeutics' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Elanco Animal Health	Positive
Gemini Therapeutics	Neutral

Summary

Elanco Animal Health beats Gemini Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Axsome Therapeutics presently has a consensus price target of $261.48, suggesting a potential upside of 8.50%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Gemini Therapeutics' return on equity of -38.78% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Gemini Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.42	-$183.17M	-$3.73	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, Axsome Therapeutics had 13 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 0 mentions for Gemini Therapeutics. Axsome Therapeutics' average media sentiment score of 1.03 beat Gemini Therapeutics' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Axsome Therapeutics	Positive
Gemini Therapeutics	Neutral

Summary

Axsome Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, Abivax had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Abivax and 0 mentions for Gemini Therapeutics. Abivax's average media sentiment score of 1.63 beat Gemini Therapeutics' score of 0.00 indicating that Abivax is being referred to more favorably in the media.

Company	Overall Sentiment
Abivax	Very Positive
Gemini Therapeutics	Neutral

47.9% of Abivax shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abivax has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 24.50%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Abivax is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Abivax beats Gemini Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Gemini Therapeutics compare to Summit Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, Summit Therapeutics had 20 more articles in the media than Gemini Therapeutics. MarketBeat recorded 20 mentions for Summit Therapeutics and 0 mentions for Gemini Therapeutics. Summit Therapeutics' average media sentiment score of 0.20 beat Gemini Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Summit Therapeutics	Neutral

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summit Therapeutics has a consensus target price of $26.15, indicating a potential upside of 91.47%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Summit Therapeutics	N/A	-183.84%	-154.65%

Summary

Summit Therapeutics beats Gemini Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Arrowhead Pharmaceuticals had 40 more articles in the media than Gemini Therapeutics. MarketBeat recorded 40 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.96 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arrowhead Pharmaceuticals	Positive

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Arrowhead Pharmaceuticals has a consensus price target of $93.83, suggesting a potential upside of 9.62%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arrowhead Pharmaceuticals	$829.45M	14.54	-$1.63M	-$2.15	N/A

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.29B	$966.52M	$6.88B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-75.86	1.53	27.00	23.71
Price / Sales	N/A	109.17	492.22	75.59
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	26.25	8.48	10.28	6.07
Net Income	-$71.87M	-$3.23M	$3.60B	$331.84M
7 Day Performance	-0.38%	-2.80%	-1.25%	-1.53%
1 Month Performance	7.80%	-4.40%	-0.35%	-2.46%
1 Year Performance	25.22%	28.83%	18.41%	13.66%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$75.86 +2.1%	N/A	+24.5%	$3.29B	N/A	N/A	30	Gap Down
ELAN Elanco Animal Health	3.7809 of 5 stars	$25.41 -0.3%	$28.73 +13.1%	+69.5%	$12.73B	$4.72B	N/A	9,400	Positive News Analyst Forecast
AXSM Axsome Therapeutics	2.7185 of 5 stars	$239.62 +1.1%	$261.48 +9.1%	+129.6%	$12.19B	$638.50M	N/A	380	Positive News
ABVX Abivax	4.0166 of 5 stars	$129.73 -3.3%	$152.50 +17.6%	+80.2%	$11.69B	N/A	N/A	61	Positive News Analyst Forecast
SMMT Summit Therapeutics	3.52 of 5 stars	$14.74 +0.8%	$26.97 +83.0%	-50.5%	$11.36B	N/A	N/A	110	Trending News Earnings Report Analyst Forecast Options Volume Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. ELAN, AXSM, ABVX, SMMT, and ARWR

How does Gemini Therapeutics compare to Elanco Animal Health?

Summary

How does Gemini Therapeutics compare to Axsome Therapeutics?

Summary

How does Gemini Therapeutics compare to Abivax?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. ELAN, AXSM, ABVX, SMMT, and ARWR

How does Gemini Therapeutics compare to Elanco Animal Health?

Which has preferable earnings and valuation, ELAN or GMTX?

Is ELAN or GMTX more profitable?

Which has more risk and volatility, ELAN or GMTX?

Do analysts prefer ELAN or GMTX?

Do institutionals and insiders believe in ELAN or GMTX?

Does the media prefer ELAN or GMTX?

Summary

How does Gemini Therapeutics compare to Axsome Therapeutics?

Do institutionals & insiders hold more shares of AXSM or GMTX?

Which has more risk and volatility, AXSM or GMTX?

Do analysts recommend AXSM or GMTX?

Is AXSM or GMTX more profitable?

Which has stronger valuation and earnings, AXSM or GMTX?

Does the media refer more to AXSM or GMTX?

Summary

How does Gemini Therapeutics compare to Abivax?

Does the media refer more to ABVX or GMTX?

Do institutionals and insiders have more ownership in ABVX or GMTX?

Which has more risk and volatility, ABVX or GMTX?

Which has stronger earnings and valuation, ABVX or GMTX?

Is ABVX or GMTX more profitable?

Do analysts prefer ABVX or GMTX?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Does the media prefer GMTX or SMMT?

Which has more volatility & risk, GMTX or SMMT?

Which has preferable earnings and valuation, GMTX or SMMT?

Do insiders and institutionals believe in GMTX or SMMT?

Do analysts rate GMTX or SMMT?

Is GMTX or SMMT more profitable?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Is GMTX or ARWR more profitable?

Does the media favor GMTX or ARWR?

Which has more volatility & risk, GMTX or ARWR?

Do analysts prefer GMTX or ARWR?

Do insiders & institutionals hold more shares of GMTX or ARWR?

Which has better valuation & earnings, GMTX or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools